Investor Presentaiton

North America: Driving Value-Play in the US market through rationalization of select product categories and ramp-up of Cipla new launches Q1FY191 30% 1 Contribution from new products launches in of Q1FY19 DTM Revenues last 12 months 19% of Q1FY19 Revenues $ Mn Q1 Y-o-Y 100 100 2 Significant Gross Margin Improvement driven by product rationalization and ramp- up of new launches +300bps Improvement in overall DTM (Cipla & Invagen) business Gross Margin% 15%pp Improvement in Cipla DTM business Gross Margin% ~$5mn impact due to rationalization of low-margin SKUs 1 Only DTM revenues of new launches considered Investor Presentation: Q1FY19 90% of new product revenues in Q1 contributed by Budesonide, Decitabine, Palonosetron & Isoproterenol Q1 FY18 Q1 FY19 Q1 Q-o-Q $ Mn 105* -5% 100 Q4 FY18 Q1 FY19 Excluding one-time income

View entire presentation